Planet 13 Holdings (PLNH) Liabilities and Shareholders Equity (2021 - 2026)
Planet 13 Holdings' (PLNH) quarterly Liabilities and Shareholders Equity came in at $146.9 million in Q1 2026, down 27.91% year-on-year from $203.8 million in Q1 2025, and down 3.52% on a QoQ basis from $152.3 million in Q4 2025.
Planet 13 Holdings (PLNH) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $146.9 million in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 27.91% year-over-year to $146.9 million in Q1 2026; TTM through Mar 2026 was $658.7 million, a 26.48% decrease from a year earlier, with the FY2025 full-year figure at $152.3 million, down 26.34% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $146.9 million, down from $152.3 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for PLNH reached as high as $274.0 million in Q1 2022 and fell as low as $146.9 million in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $204.1 million across 5 years, with a median of $206.7 million in 2023.
- Across the five-year window, Liabilities and Shareholders Equity slumped 38.46% in 2023 and jumped 49.89% in 2024, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $220.1 million in 2022, then tumbled by 31.04% to $151.7 million in 2023, then soared by 36.24% to $206.7 million in 2024, then dropped by 26.34% to $152.3 million in 2025, then declined by 3.52% to $146.9 million in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $146.9 million in Q1 2026, $152.3 million in Q4 2025, and $158.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Planet 13 Holdings | 39.35 Mn | 23.09 Mn | 9.41 Mn | 146.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.91 Mn |
| Dec 31, 2025 | 152.28 Mn |
| Sep 30, 2025 | 158.50 Mn |
| Jun 30, 2025 | 200.98 Mn |
| Mar 31, 2025 | 203.79 Mn |
| Dec 31, 2024 | 206.73 Mn |
| Sep 30, 2024 | 242.96 Mn |
| Jun 30, 2024 | 242.43 Mn |
| Mar 31, 2024 | 157.39 Mn |
| Dec 31, 2023 | 151.75 Mn |
| Sep 30, 2023 | 162.10 Mn |
| Jun 30, 2023 | 206.70 Mn |
| Mar 31, 2023 | 211.48 Mn |
| Dec 31, 2022 | 220.06 Mn |
| Sep 30, 2022 | 263.41 Mn |
| Jun 30, 2022 | 268.44 Mn |
| Mar 31, 2022 | 274.00 Mn |
| Dec 31, 2021 | 213.81 Mn |